| Similar Articles |
|---|
 |
Chemistry World
May 8, 2012
Helen Carmichael |
Pharma firms see mixed fortunes in Quebec Quebec's life sciences and pharmaceutical industry has suffered several blows in 2012, with hundreds of R&D jobs being lost. This comes despite the industry receiving hundreds of millions of dollars in government assistance and favorable tax rates.   |
Chemistry World
September 17, 2012
Andrew Turley |
Drug discovery becomes Facebook game German drug maker Boehringer Ingelheim has launched a game based on the drug discovery process. |
Chemistry World
September 6, 2012
Andrew Turley |
Valeant buys $2.6bn skincare firm Canadian pharma company Valeant is to buy US firm Medicis in a $2.6 billion deal. Medicis produces prescription dermatology products as well as over the counter products. |
Chemistry World
December 10, 2012
Andrew Turley |
EU companies increasing R&D Companies in the EU are increasing their investment in R&D, despite the difficult economic conditions, according to a report from the European Commission that looked at the global top 1500 R&D investors. |
Pharmaceutical Executive
December 1, 2013 |
Country Report: Canada Despite declining investments by big pharma in recent years, Canada has created a number of innovative ways to incentivize R&D and leverage its geographic reach in the North American Market. |
Chemistry World
February 2, 2012
Andrew Turley |
AstraZeneca to cut 7300 more jobs UK drugmaker AstraZeneca has announced plans to cut a further 7300 jobs to make annual savings of $1.6 billion by the end of 2014, a move that will cost the company $2.1 billion in the near term. |
Chemistry World
July 29, 2015
Phillip Broadwith |
Hikma boosts generics with Roxane buyout UK-headquartered Hikma Pharmaceuticals has agreed to buy Roxane Laboratories -- Boehringer Ingelheim's generic medicines unit -- for a total of $2.65 billion. |
The Motley Fool
July 30, 2007
Brian Lawler |
AstraZeneca's Yawner of a Quarter The pharma's second-quarter results are ho-hum. Investors may do well to take a look at some of the other big pharma stocks, which offer more compelling reasons to buy. |
Chemistry World
September 26, 2014
Rebecca Trager |
Merck KGaA to buy Sigma--Aldrich German chemicals conglomerate Merck KGaA has agreed to buy US specialty chemicals company Sigma -- Aldrich for $17 billion |
Entrepreneur
August 2003
Joshua Kurlantzick |
Northern Exposure American entrepreneurs are finding success by heading for the border. |
The Motley Fool
March 19, 2004
Bill Mann |
The Drug Reimportation Disaster State-imposed pricing is not natural law. Expect Canada to have a problem supplying all those drugs. |
Chemistry World
November 3, 2014
Phillip Broadwith |
Chinese buyer resurrects US Boehringer plant Chinese company UniTao has agreed to buy a Boehringer Ingelheim manufacturing site in Petersburg, US, which was scheduled to be closed by the end of the year with the loss of 240 jobs. |
The Motley Fool
January 12, 2011
Brian Orelli |
Drugmaker Math: 4 Halves Beat 2 Wholes Eli Lilly and Boehringer Ingelheim hook up. |
The Motley Fool
June 1, 2006
Stephen D. Simpson |
Bonjour, Bank of Montreal! There may be little separating the United States and Canada in some respects, but you don't hear a lot of talk about Canadian equities on this side of the border. This stock might be a safer play on Canada. |
Pharmaceutical Executive
April 1, 2011 |
How US Health Reform Is Hitting Canada Canada's Russell Williams, of Rx&D, talks about the impact of US health reform on his role as chief spokesman for the country's R&D industry. |
Pharmaceutical Executive
October 1, 2006
Sarah Houlton |
Global Report: Please Come Back Health authorities in Europe are working hard to reestablish their countries as preferred locations for pharma's R&D facilities. Fortunately, they've got a blueprint: China. |
Bio-IT World
December 10, 2002
Malorye Branca |
The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D. |
Chemistry World
July 3, 2012
Andrew Turley |
BMS and AstraZeneca buy Amylin for $7bn Pharma giants Bristol-Myers Squibb and AstraZeneca have teamed up to buy US biotech Amylin for $7 billion, further strengthening their position in the burgeoning market for diabetes drugs. |
The Motley Fool
October 7, 2011
Brian Orelli |
A Little Help, Please Gilead pumps up the pipeline. |
The Motley Fool
March 22, 2011
Brian Orelli |
Pharmas in the Doghouse Merck and Sanofi call off their joint venture. |
Financial Advisor
February 2010
Jeff Schlegel |
Going For Gold The Winter Olympics come to Vancouver this month, shining a light on Canada -- and its investment opportunities. |
The Motley Fool
October 17, 2007
Tom Taulli |
Rodman & Renshaw Clones a Bear The biotech boutique has a shaky public offering. |
The Motley Fool
July 2, 2010
Gerard Torres |
Go Canada for Your Banking Buys With a booming economy, Canadian banks are looking like good investments. |
Chemistry World
August 20, 2013
Phillip Broadwith |
Boehringer to close manufacturing plants and cut jobs Boehringer Ingelheim is closing two US manufacturing plants, with a combined loss of 690 jobs. |
The Motley Fool
January 15, 2010
Brian Orelli |
Oops, Sorry About That, Pfizer The FDA says there's no problem with Spiriva after all. |
The Motley Fool
May 26, 2011
Brian Orelli |
Amylin Scores First in Court But it is still early innings. |
The Motley Fool
March 8, 2010
Brian Orelli |
Pfizer Still Dealing With Antitrust Issues The pharma giant sells off some more animal health assets. |
Bio-IT World
May 2006 |
News Blast Ingenious... Partners... Integration... |
Bio-IT World
December 10, 2002
Jim Hall |
21st Century R&D Strategy: Atlantic or Pacific? The biopharmaceutical sector is divided by two strategic perspectives. |
The Motley Fool
April 19, 2004
Ben McClure |
Ruminations on R&D Spending on research and development is important. But can it help identify promising investments? It's pretty easy to spot companies that spend a lot of money on R&D. It's another thing to pick companies that translate R&D spending into higher stock prices. |
The Motley Fool
November 15, 2010
Brian Orelli |
A Mega-Blockbuster Showdown Boehringer Ingelheim's Pradaxa was recently approved to treat patients with an erratic heartbeat, and Bayer and Johnson & Johnson have a second compound, Xarelto, that isn't far behind. |
